Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.55
CHRS's Cash to Debt is ranked lower than
74% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. CHRS: 1.55 )
Ranked among companies with meaningful Cash to Debt only.
CHRS' s Cash to Debt Range Over the Past 10 Years
Min: 1.55  Med: N/A Max: No Debt
Current: 1.55
Equity to Asset 0.17
CHRS's Equity to Asset is ranked lower than
88% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CHRS: 0.17 )
Ranked among companies with meaningful Equity to Asset only.
CHRS' s Equity to Asset Range Over the Past 10 Years
Min: -2.05  Med: 0.14 Max: 0.39
Current: 0.17
-2.05
0.39
F-Score: 3
Z-Score: 1.35
M-Score: 3.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -47.47
CHRS's Operating margin (%) is ranked higher than
56% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. CHRS: -47.47 )
Ranked among companies with meaningful Operating margin (%) only.
CHRS' s Operating margin (%) Range Over the Past 10 Years
Min: -2028.33  Med: -1018.8 Max: -47.47
Current: -47.47
-2028.33
-47.47
Net-margin (%) -52.04
CHRS's Net-margin (%) is ranked higher than
55% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. CHRS: -52.04 )
Ranked among companies with meaningful Net-margin (%) only.
CHRS' s Net-margin (%) Range Over the Past 10 Years
Min: -1949.65  Med: -1240.94 Max: -52.04
Current: -52.04
-1949.65
-52.04
ROA (%) -47.86
CHRS's ROA (%) is ranked lower than
65% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. CHRS: -47.86 )
Ranked among companies with meaningful ROA (%) only.
CHRS' s ROA (%) Range Over the Past 10 Years
Min: -145  Med: -118.09 Max: -47.86
Current: -47.86
-145
-47.86
ROC (Joel Greenblatt) (%) -987.52
CHRS's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. CHRS: -987.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CHRS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2990.18  Med: -2783.84 Max: -987.52
Current: -987.52
-2990.18
-987.52
» CHRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CHRS Guru Trades in Q4 2015

George Soros 127,600 sh (unchged)
Jim Simons Sold Out
» More
Q1 2016

CHRS Guru Trades in Q1 2016

Steven Cohen 131,200 sh (New)
George Soros Sold Out
» More
Q2 2016

CHRS Guru Trades in Q2 2016

Paul Tudor Jones 11,300 sh (New)
Jim Simons 94,500 sh (New)
Steven Cohen 37,500 sh (-71.42%)
» More
Q3 2016

CHRS Guru Trades in Q3 2016

Joel Greenblatt 17,363 sh (New)
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 10,670 sh (-5.58%)
» More
» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:EBS, OTCPK:MPSYY, NAS:DERM, OTCPK:SXMDF, NAS:FOLD, NAS:ALDR, NAS:AMAG, NAS:RGEN, NAS:INVA, NAS:XNCR, NAS:ARRY, NAS:PTLA, OTCPK:PFSCF, NAS:BGNE, NAS:FWP, NAS:OPHT, NAS:AIMT, NYSE:AXON, NAS:BPMC, NAS:CORT » details
Coherus BioSciences Inc is a late-stage clinical biologics platform company. The Company is engaged in developing biosimilar therapeutics.

Top Ranked Articles about Coherus BioSciences Inc

Coherus Biosciences' Humira Petition Denied AbbVie’s Humira patent remains untouched
AbbVie’s (NYSE:ABBV) shareholders received positive news from the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office in regard to the legitimacy of AbbVie’s Humira formulation patent. Read more...

Ratios

vs
industry
vs
history
P/B 37.19
CHRS's P/B is ranked lower than
96% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CHRS: 37.19 )
Ranked among companies with meaningful P/B only.
CHRS' s P/B Range Over the Past 10 Years
Min: 6.35  Med: 22.19 Max: 41.14
Current: 37.19
6.35
41.14
P/S 6.84
CHRS's P/S is ranked higher than
62% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. CHRS: 6.84 )
Ranked among companies with meaningful P/S only.
CHRS' s P/S Range Over the Past 10 Years
Min: 6.54  Med: 16.85 Max: 35.73
Current: 6.84
6.54
35.73
EV-to-EBIT -11.94
CHRS's EV-to-EBIT is ranked lower than
99.99% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. CHRS: -11.94 )
Ranked among companies with meaningful EV-to-EBIT only.
CHRS' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.6  Med: -4.2 Max: 0.6
Current: -11.94
-15.6
0.6
EV-to-EBITDA -12.28
CHRS's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. CHRS: -12.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
CHRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16  Med: -4.2 Max: 0.6
Current: -12.28
-16
0.6
Current Ratio 3.04
CHRS's Current Ratio is ranked lower than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CHRS: 3.04 )
Ranked among companies with meaningful Current Ratio only.
CHRS' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.47 Max: 3.46
Current: 3.04
0.85
3.46
Quick Ratio 3.04
CHRS's Quick Ratio is ranked lower than
60% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CHRS: 3.04 )
Ranked among companies with meaningful Quick Ratio only.
CHRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.47 Max: 3.46
Current: 3.04
0.85
3.46
Days Sales Outstanding 0.77
CHRS's Days Sales Outstanding is ranked higher than
98% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. CHRS: 0.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.77  Med: 29.37 Max: 36.88
Current: 0.77
0.77
36.88

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 68.29
CHRS's Price/Net Current Asset Value is ranked lower than
97% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. CHRS: 68.29 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CHRS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 9.22  Med: 28.23 Max: 68.66
Current: 68.29
9.22
68.66
Price/Tangible Book 41.79
CHRS's Price/Tangible Book is ranked lower than
96% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CHRS: 41.79 )
Ranked among companies with meaningful Price/Tangible Book only.
CHRS' s Price/Tangible Book Range Over the Past 10 Years
Min: 8.58  Med: 21.01 Max: 42.01
Current: 41.79
8.58
42.01
Price/Median PS Value 0.41
CHRS's Price/Median PS Value is ranked higher than
84% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CHRS: 0.41 )
Ranked among companies with meaningful Price/Median PS Value only.
CHRS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 0.95 Max: 1.67
Current: 0.41
0.39
1.67
Earnings Yield (Greenblatt) (%) -8.35
CHRS's Earnings Yield (Greenblatt) (%) is ranked higher than
50% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CHRS: -8.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CHRS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -64.62  Med: 0 Max: 0
Current: -8.35
-64.62
0

More Statistics

Revenue (TTM) (Mil) $199.5
EPS (TTM) $ -3.05
Short Percentage of Float18.87%
52-Week Range $12.04 - 31.98
Shares Outstanding (Mil)43.65
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
Coherus Biosciences' Humira Petition Denied Nov 08 2016 
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US :... Dec 06 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 30 2016
Coherus’ Marketing Authorization Application to European Medicines Agency for CHS-1701... Nov 29 2016
Is The Rubicon Project Inc (RUBI) A Good Stock To Buy? Nov 28 2016
Coherus BioSciences Announces New Employment Inducement Grants Nov 17 2016
Coherus BioSciences Announces New Employment Inducement Grants Nov 17 2016
COHERUS BIOSCIENCES, INC. Financials Nov 17 2016
Coherus BioSciences posts 3Q profit Nov 10 2016
Coherus BioSciences posts 3Q profit Nov 10 2016
Edited Transcript of CHRS earnings conference call or presentation 9-Nov-16 9:30pm GMT Nov 09 2016
Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today Nov 09 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 09 2016
Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results Nov 09 2016
Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results Nov 09 2016
AbbVie Inc (ABBV) Wins Patent Battle Against Coherus Biosciences Inc (CHRS) Nov 09 2016
Q3 2016 Coherus BioSciences Inc Earnings Release - After Market Close Nov 09 2016
Coherus Biosciences' Humira Petition Denied Nov 08 2016
AbbVie Crushes Humira Patent Challenge (ABBV, CHRS) Nov 08 2016
Drug Stock Earnings to Watch on Nov 9: MYL, IONS & More Nov 08 2016
AbbVie Inc (ABBV) Stock: Skyrocketing On IP Chatter | Coherus Biosciences Inc (CHRS) Stock Tanking Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)